logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

RCC: sequential ipilimumab in nivolumab-nonresponsive disease yields low response

Findings do not support a response-based adaptive strategy for nivolumab, ipilimumab.